Clearstone Central Laboratories
announced that it has entered into a partnership with
Mitsubishi Chemical Medience Corporation
(Mitsubishi). This preferred provider relationship provides clients of both companies with access to CAP-accredited laboratories for safety and specialty testing services throughout the Asia-Pacific region and around the world. The cross-collaboration opens access for Mitsubishi clients not only to Clearstone’s lab in China but to its global laboratory network, and creates a new solution for Clearstone clients to access Mitsubishi’s lab network in Japan.
“We are very pleased to announce the Mitsubishi partnership given the value and opportunities it creates for our clients”, said Clearstone CEO Lewis Cameron. “Mitsubishi is well established in Japan, and this agreement extends their reach and capabilities to other strategic markets, including our renowned laboratory in China. We look forward to aligning our operational and business development activities, as well as providing our clients with access to the Japanese market”.
This announcement follows a collaborative agreement that Clearstone signed with the Esoterix Clinical Trials Services division of LabCorp last year.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.